Lyell Immunopharma | SC 13G/A:超过5%持股股东披露文件(修正)-The Vanguard Group(3.93%)
Lyell Immunopharma | 10-Q:2024财年三季报
Lyell Immunopharma | 8-K:Lyell Immunopharma报告2024年第三季度的业务亮点和财务业绩
Lyell Immunopharma | SC 13G/A:超过5%持股股东披露文件(修正)-The Vanguard Group(3.93%)
Lyell Immunopharma | 3:首次持股声明-董事 Ramachandra Sumant
Lyell Immunopharma | 4:持股变动声明-董事 Ramachandra Sumant
Lyell Immunopharma | SC 13G:超过5%持股股东披露文件-James Tananbaum (“Tananbaum”)(5.3%),Foresite Capital Fund IV, L.P. (“FCF IV”)(3.2%)等
Lyell Immunopharma | 8-K:重大事件
Lyell Immunopharma | 8-K:重大事件
Lyell Immunopharma | 10-Q:2024财年二季报
Lyell Immunopharma | 8-K:Lyell Immunopharma报告2024年第二季度的业务亮点和财务业绩
Lyell Immunopharma | 8-K:重大事件
Lyell Immunopharma | 4:持股变动声明-董事 NELSEN ROBERT
Lyell Immunopharma | 4:持股变动声明-董事 Klausner Richard
Lyell Immunopharma | 4:持股变动声明-董事 Bishop Hans Edgar
Lyell Immunopharma | 4:持股变动声明-董事 RIEFLIN WILLIAM JL
Lyell Immunopharma | 4:持股变动声明-董事 NABEL ELIZABETH G
Lyell Immunopharma | 4:持股变动声明-董事 BRAWLEY OTIS W
Lyell Immunopharma | 4:持股变动声明-董事 FRIEDMAN CATHY
Lyell Immunopharma | 8-K:重大事件
暂无数据
暂无数据